1.Sales and profit
See section β- Acrivon Therapeutics, Inc. lost $77.9M in fiscal 2025.
Acrivon Therapeutics, Inc.
ACRV Nasdaq Pharmaceutical Preparations Financials FY2021βFY2025
Download report
3-page PDF: the company, its results and charts with peers.
Last close Β· Oct 23, 2026
$1.73
1.7%KIRAβs summary AI analyst
Hi! I read Acrivon Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$65.3M in fiscal 2025, β of revenue.
- In the last 12 months, insiders bought $0.1M and sold $0.0M of shares on the open market.
Acrivon Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$77.9M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$72.4M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$1.88 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Acrivon Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
- Time
- Time not announced
- Covers
- Period ended Sep 30, 2026
- Expected EPS
- β$0.45
- Source
- Earnings calendar
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 12, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 8, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 13, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 13, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 14, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 25, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 13, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY21
Revenue β
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Acrivon Therapeutics, Inc. lost $77.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY21
Net income β$16.2M
FY22
Net income β$31.2M
FY23
Net income β$60.4M
FY24
Net income β$80.6M
FY25
Net income β$77.9M
Net income
Q3 '23
Net income β$14.5M
Q4 '23
Net income β$19.3M
Q1 '24
Net income β$16.5M
Q2 '24
Net income β$18.8M
Q3 '24
Net income β$22.4M
Q4 '24
Net income β$22.8M
Q1 '25
Net income β$19.7M
Q2 '25
Net income β$21.0M
Q3 '25
Net income β$18.2M
Q4 '25
Net income β$19.0M
Q1 '26
Net income β$19.0M
Q2 '26
Net income β$18.0M
Diluted EPS
FY21
Diluted EPS β$9.32
FY22
Diluted EPS β$7.56
FY23
Diluted EPS β$2.74
FY24
Diluted EPS β$2.38
FY25
Diluted EPS β$2.02
Diluted EPS
Q3 '23
Diluted EPS β$0.66
Q4 '23
Diluted EPS β$0.87
Q1 '24
Diluted EPS β$0.73
Q2 '24
Diluted EPS β$0.52
Q3 '24
Diluted EPS β$0.59
Q4 '24
Diluted EPS β$0.54
Q1 '25
Diluted EPS β$0.51
Q2 '25
Diluted EPS β$0.55
Q3 '25
Diluted EPS β$0.47
Q4 '25
Diluted EPS β$0.49
Q1 '26
Diluted EPS β$0.49
Q2 '26
Diluted EPS β$0.43
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$65.3M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY21
Free cash flow β$14.2M
FY22
Free cash flow β$32.3M
FY23
Free cash flow β$43.9M
FY24
Free cash flow β$68.4M
FY25
Free cash flow β$65.3M
Free cash flow
Q3 '23
Free cash flow β$9.8M
Q4 '23
Free cash flow β$13.5M
Q1 '24
Free cash flow β$17.9M
Q2 '24
Free cash flow β$14.0M
Q3 '24
Free cash flow β$18.3M
Q4 '24
Free cash flow β$18.2M
Q1 '25
Free cash flow β$19.6M
Q2 '25
Free cash flow β$17.1M
Q3 '25
Free cash flow β$13.2M
Q4 '25
Free cash flow β$15.5M
Q1 '26
Free cash flow β$20.6M
Q2 '26
Free cash flow β$14.9M
Cash from operations vs capital spending
FY21
Cash from operations β$14.0M
Capital spending $0.2M
FY22
Cash from operations β$30.1M
Capital spending $2.2M
FY23
Cash from operations β$42.6M
Capital spending $1.3M
FY24
Cash from operations β$65.7M
Capital spending $2.8M
FY25
Cash from operations β$63.7M
Capital spending $1.7M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$9.8M
Capital spending $0.0M
Q4 '23
Cash from operations β$12.4M
Capital spending $1.2M
Q1 '24
Cash from operations β$17.1M
Capital spending $0.8M
Q2 '24
Cash from operations β$13.9M
Capital spending $0.1M
Q3 '24
Cash from operations β$17.3M
Capital spending $1.0M
Q4 '24
Cash from operations β$17.4M
Capital spending $0.8M
Q1 '25
Cash from operations β$19.5M
Capital spending $0.1M
Q2 '25
Cash from operations β$16.6M
Capital spending $0.5M
Q3 '25
Cash from operations β$12.3M
Capital spending $0.9M
Q4 '25
Cash from operations β$15.2M
Capital spending $0.2M
Q1 '26
Cash from operations β$20.5M
Capital spending $0.0M
Q2 '26
Cash from operations β$14.9M
Capital spending $0.1M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.02B
FY24
Diluted shares 0.03B
FY25
Diluted shares 0.04B
Insider trades
KIRA Β· In the last 12 months, insiders bought $0.1M and sold $0.0M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.1M
3 insiders
Sold, 12 months
$0.0M
7 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | Mary MillerChief Legal Officer | Sold | 294 | $1.99 | $0.0M | Form 4 |
| Aug 25, 2026 | Peter Blume-JensenPresident and CEO, Director | Sold | 14,036 | $2.21 | $0.0M | Form 4 |
| Aug 18, 2026 | Eric DevroeChief Operating Officer | Sold | 604 | $2.01 | $0.0M | Form 4 |
| Aug 18, 2026 | Erick GamelinChief Development Officer | Sold | 400 | $2.01 | $0.0M | Form 4 |
| Aug 18, 2026 | Katharine PetersonChief Accounting Officer | Sold | 101 | $2.01 | $0.0M | Form 4 |
| Aug 18, 2026 | Kristina MassonEVP - Business Operations, Director | Sold | 1,713 | $2.01 | $0.0M | Form 4 |
| Aug 18, 2026 | Mary MillerChief Legal Officer | Sold | 185 | $2.01 | $0.0M | Form 4 |
| Aug 4, 2026 | Adam D. LevyChief Financial Officer | Sold | 1,142 | $1.57 | $0.0M | Form 4 |
| Jul 21, 2026 | Mary MillerChief Legal Officer | Sold | 573 | $1.76 | $0.0M | Form 4 |
| Jan 14, 2026 | Adam D. LevyChief Financial Officer | Bought | 8,832 | $1.70 | $0.0M | Form 4 |
| Jan 14, 2026 | Peter Blume-JensenPresident and CEO, Director | Bought | 49,000 | $1.68 | $0.1M | Form 4 |
| Jan 13, 2026 | Eric DevroeChief Operating Officer | Bought | 10,000 | $1.72 | $0.0M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Acrivon Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY21
Cash $99.6M
Debt β
FY22
Cash $128M
Debt β
FY23
Cash $127M
Debt β
FY24
Cash $179M
Debt β
FY25
Cash $119M
Debt β
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $99.6M | $128M | $127M | $179M | $119M |
| Current ratio | 34.5x | 20.3x | 9.7x | 10.6x | 7.7x |
| Quick ratio | 34.5x | 20.3x | 9.7x | 10.6x | 7.7x |
| Total assets | $107M | $181M | $138M | $197M | $130M |
| Total liabilities | $7.9M | $10.8M | $17.1M | $19.8M | $17.2M |
| Shareholders' equity | β$23.8M | $170M | $121M | $177M | $113M |
| Net debt (β = net cash) | β | β | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY21
Return on capital β
Return on equity β
Return on assets β15.2%
FY22
Return on capital β
Return on equity β42.5%
Return on assets β21.7%
FY23
Return on capital β
Return on equity β41.4%
Return on assets β37.8%
FY24
Return on capital β
Return on equity β54.1%
Return on assets β48.1%
FY25
Return on capital β
Return on equity β53.9%
Return on assets β47.7%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 |
| Accruals ratio | β2.1% | β0.7% | β11.1% | β8.9% | β8.7% |
| Altman Z'' | 1.05 | 18.98 | 6.97 | 8.54 | 0.90 |
All figures
Every number, year by year.
5 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Research and development | β | $23.9M | $46.0M | $64.0M | $60.0M |
| Operating income | β$16.2M | β$32.7M | β$67.1M | β$89.2M | β$84.1M |
| Pretax income | β | β | β | β$80.4M | β$77.8M |
| Income tax | β | β | β | β | $0.0M |
| Net income | β$16.2M | β$31.2M | β$60.4M | β$80.6M | β$77.9M |
| Diluted EPS | β$9.32 | β$7.56 | β$2.74 | β$2.38 | β$2.02 |
| Diluted shares | 0.00B | 0.00B | 0.02B | 0.03B | 0.04B |
| Cash flow | |||||
| Cash from operations | β$14.0M | β$30.1M | β$42.6M | β$65.7M | β$63.7M |
| Capital expenditure | $0.2M | $2.2M | $1.3M | $2.8M | $1.7M |
| Free cash flow | β$14.2M | β$32.3M | β$43.9M | β$68.4M | β$65.3M |
| Depreciation and amortization | $0.0M | $0.4M | $0.5M | $1.0M | $1.4M |
| Stock-based compensation | $0.5M | $2.2M | $11.6M | $14.3M | $14.7M |
| Balance sheet | |||||
| Cash and short-term investments | $99.6M | $128M | $127M | $179M | $119M |
| Current assets | $100M | $132M | $130M | $182M | $120M |
| Current liabilities | $2.9M | $6.5M | $13.3M | $17.2M | $15.7M |
| Property and equipment, net | $0.3M | $2.1M | $3.5M | $4.5M | $4.9M |
| Total assets | $107M | $181M | $138M | $197M | $130M |
| Total liabilities | $7.9M | $10.8M | $17.1M | $19.8M | $17.2M |
| Shareholders' equity | β$23.8M | $170M | $121M | $177M | $113M |
| Returns | |||||
| Return on capital employed | β15.6% | β18.7% | β53.7% | β49.7% | β73.7% |
| Return on equity | β | β42.5% | β41.4% | β54.1% | β53.9% |
| Return on assets | β15.2% | β21.7% | β37.8% | β48.1% | β47.7% |
| Return on tangible equity | β | β18.3% | β49.8% | β45.6% | β69.2% |
| Growth | |||||
| Share count change | β | 136.4% | 435.6% | 53.1% | 14.0% |
| Financial health | |||||
| Current ratio | 34.5x | 20.3x | 9.7x | 10.6x | 7.7x |
| Quick ratio | 34.5x | 20.3x | 9.7x | 10.6x | 7.7x |
| Quality scores | |||||
| Altman Z'' | 1.0 | 19.0 | 7.0 | 8.5 | 0.9 |
| Accruals ratio | β2.1% | β0.7% | β11.1% | β8.9% | β8.7% |
Source: SEC EDGAR XBRL filings (CIK 0001781174). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.